By Ted Bosworth
New Orleans—A genomic assay can help determine whether adjuvant therapy is needed in patients who have completed local treatment for early breast cancer, according to a large, randomized trial.
In this trial, the genomic assay demonstrated that almost half of those patients who met the clinical criteria for chemotherapy could forgo this treatment without jeopardizing their outcomes at five years.
The study is not the first to demonstrate the value of genomic profiling, but